COVID-19 and Liver Injury in Patients With or Without Underlying Liver Disease: A Multi-centre Retrospective-prospective Observational Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04422379

Enrollment

314

Registered

2020-06-09

Start date

2020-06-07

Completion date

2020-08-30

Last updated

2020-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

Detailed description

COVID-19 and liver injury in patients with or without underlying liver disease: A multi-centre retrospective-prospective observational study. All patients infected with SARS-CoV-2 and admitted to the COVID-19 ward/ICU of Max Hospital Saket (either in East Wing , Max Super Specialty Hospital, Saket or MAX Smart Super Specialty Hospital, Saket) between 1/4/2020 to 30/6/2020 (retrospective data between 1/4/2020- 30/5/2020 & prospective data from approval till 30/6/2020), will be included Primary objectives 1. To study the prevalence of liver live injury & factors associated with among patients in-fected with SARS-CoV-2. 2. To study the prevalence of new liver injury and factors associated with it, among patient with underlying liver disease who develops COVD-19. Secondary objectives 1. To correlate the presence and degree of liver dysfunction with the clinical outcomes in these patients. 2. To define the incidence of development of acute liver failure among these patients

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

All patients infected with SARS-CoV-2 and admitted to the COVID-19 ward/ICU of Max Hospital Saket (either in East Wing , Max Super Specialty Hospital, Saket or MAX Smart Super Specialty Hospital, Saket) between 1/4/2020 to 30/6/2020 (retrospective data between 1/4/2020- 30/5/2020 & prospective data from approval till 30/6/2020), will be included. \-

Exclusion criteria

1. Patients less that 18 years old with COVID-19 2. Pregnant ladies with COVD-19 3. Unwilling to give consent for inclusion

Design outcomes

Primary

Measure	Time frame	Description
COVID-19 Positive Case	4-8 weeks	To study the prevalence of liver live injury & factors associated with among patients in-fected with SARS-CoV-2.

Secondary

Measure	Time frame	Description
COVID-19 Positive Case	4-8 weeks	To correlate the presence and degree of liver dysfunction with the clinical outcomes in these patients.

Countries

India

Contacts

Primary ContactKaushal Madan, DM

K_madan_2000@yahoo.com9958787720

Backup ContactVivek Raj, DM

Vivek.Raj@maxhealthcare.com9818921051

Outcome results